Company ProfilePremium

Anuh Pharma Limited

Company Profile Analysis

Tickers: ANUHPHR.NS, 506260.BO

ESOMAR 23 Corporate BadgeISO Certifications Badge
Anuh Pharma Limited - Company showcase

Year Founded & Workforce

1960

323 Employees

Anuh Pharma Limited logo

Anuh Pharma Limited Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Anuh Pharma Limited Overview

Anuh Pharma is a small-cap, single-site, debt-free Indian manufacturer of active pharmaceutical ingredients (APIs). Its business rests on off-patent, mature anti-infective molecules. It claims to be India's largest producer of erythromycin salts, among the top five globally, and the world's largest producer of pyrazinamide (ICRA, Sep 2025). Its Tarapur (Boisar) plant has 2,400 MTPA of capacity across nine API blocks and two intermediate blocks. The plant holds approvals from USFDA (a no-observation inspection in early 2026), EU GMP (Spanish AEMPS), WHO pre-qualification, and multiple EDQM CEPs. Anuh sells to about 360 customers and marketing partners in more than 72 countries. Exports were about 46% of FY26 revenue, mainly to Asia, Africa and Europe. FY26 revenue from operations was INR 771.7 Cr (+16.7%). Margins, however, compressed to an EBITDA margin of 8.6% because of price competition in commoditised molecules. Management's strategy is to move volume toward regulated markets and newer molecules (anti-diabetics, anti-coagulants, new anti-TB and anti-malarials) while keeping the balance sheet ungeared. It guides to 15–20% annual growth.


What the company does

Anuh Pharma makes and sells bulk drugs (APIs) and some intermediates. Pharmaceutical formulators in India and abroad buy these and turn them into finished dosage forms.

Under Ind AS 108, the company reports a single operating segment, "Bulk drugs and Chemicals". It therefore publishes no segment financials (FY25 audited results, note 6; Q3 FY26 results, note 7).

The portfolio covers 12 therapeutic categories:

  • macrolides (erythromycin salts)

  • higher macrolides (azithromycin)

  • corticosteroids (15 molecules)

  • anti-TB (pyrazinamide, isoniazid)

  • anti-malarials (sulfadoxine, pyrimethamine, amodiaquine)

  • anti-diabetics (gliclazide, vildagliptin, dapagliflozin)

  • anti-bacterials (chloramphenicol and its palmitate)

  • expectorants (ambroxol HCl, acefylline piperazine)

  • an anti-asthmatic (acebrophylline)

  • an antihistamine (bilastine, listed as "Bilsatin")

  • a quinolone (moxifloxacin)

  • an antibiotic (sulfadimethoxine)

  • an anti-gout drug (allopurinol)

Source: Q1 FY27 investor presentation, Aug 2026.

Company's own description

In its investor materials, the company describes itself as one of India's largest makers of macrolides and anti-TB products. It also calls itself a significant player in anti-bacterials, anti-malarials, anti-hypertensives and corticosteroids, with marketing partnerships across about 360 customers in more than 72 countries, including Europe, Mexico and South Africa.

It lists leading positions in:

  • erythromycin salts

  • pyrazinamide

  • sulfadoxine

  • ambroxol HCl

  • gliclazide

  • clobetasol propionate

  • betamethasone dipropionate

The reasons it gives for customer preference are:

  • regulatory approvals

  • EHS compliance audited by multinationals

  • diversified sourcing with backward integration in key products

  • spare capacity

  • a debt-free balance sheet with steady dividends

  • a DSIR-approved R&D centre

Source: Q1 FY27 investor presentation; FY25 annual report summary as reproduced by Screener.

Business model and revenue model

DimensionCharacterisation
Revenue model mixAbout 100% product sales (API manufacturing plus some traded goods). No subscription, licensing or service revenue is disclosed. Purchases of stock-in-trade were INR 79.2 Cr in FY26 (about 10% of revenue from operations), against INR 38.5 Cr in FY25. Trading is therefore a material and growing secondary activity.
PricingSpot and contract pricing for generic APIs, plus institutional tenders. The WHO-prequalified anti-malarials and anti-TB molecules feed donor-funded procurement chains.
Value-chain positionMid-stream. Anuh buys key starting materials and intermediates (for example erythromycin thiocyanate, mostly from fermentation-based producers, and steroid intermediates), converts them into salts and APIs, and sells to formulators. ICRA credits selective backward integration in key products.
Customer typesDomestic and international generic formulators, multinational pharma companies (which audit the site), marketing and trading partners, and institutional and tender-linked buyers for WHO-PQ molecules.
ConcentrationTop-five customers took 42% of FY26 export sales (FY26 investor presentation). Top-five customers' share of total sales fell to 20% in Q1 FY27 from 36% in Q1 FY26 (Q1 FY27 presentation).
End-marketsDomestic India (about 54% of FY26 revenue). Export (about 46%) to Asia 35%, Africa 33%, Europe 24%, North America 5% and Latin America 3% (FY26 investor presentation).

Sources: FY26 audited results (20 May 2026); Q1 FY27 results (7 Aug 2026); FY26 and Q1 FY27 investor presentations.

Independent characterisation

Anuh is a commodity-API converter. Its competitive edge comes from three things: regulatory credentials (EU GMP, CEPs, WHO-PQ and now a clean USFDA inspection), process cost, and customer relationships. It does not rely on intellectual property.

Most of its revenue comes from mature, multi-sourced molecules. ICRA's September 2025 rationale says this exposes margins to price competition and raw-material swings. Erythromycin alone was about 31% of FY26 product revenue (INR 241 Cr of INR 772 Cr).

The business is lightly capitalised. Net fixed assets were about INR 56 Cr against INR 772 Cr of revenue in FY26. Working-capital intensity is high and rising: the cash conversion cycle went from 58 days in FY22 to 86 days in FY26.

The balance sheet is very conservative. Total debt was effectively nil at FY26 year-end, and the company held about INR 53 Cr of cash and liquid investments plus INR 40 Cr of long-term investments.

Management's strategic intent is to shift the mix toward regulated markets and toward molecules with less commoditised pricing. Q1 FY27 margin expansion is the first evidence that this is working.

Strategy

Stated strategy

These themes are paraphrased from the FY26 and Q1 FY27 investor presentations ("Future Outlook — Growth Strategy"):

  1. Volume expansion with regulated-market growth. Grow volumes across API lines while shifting toward higher-value regulated markets. The USFDA and EU GMP clearances are described as making the regulated-market pipeline the primary growth engine.

  2. Process innovation and cost optimisation, as a continuing priority for competitiveness in commoditised molecules.

  3. Market diversification focused on exports, explicitly framed as reducing currency risk.

  4. Continued investment in compliance, operational efficiency and capacity, funded internally.

  5. Portfolio diversification and operating leverage, from new molecules and better throughput of existing assets.

The Joint MDs' Q1 FY27 letter credits three levers for margin improvement: a richer product mix, disciplined cost control, and higher throughput from existing assets.

Initiatives in the last 24 months

InitiativeDateDetailStatus
Capacity expansion to 2,200 MTPAFY25 (around Mar 2025)Funded by internal accruals; FY25 capex about INR 20 CrCompleted
Capacity expansion to 2,400 MTPAEffective 15 Jul 202540 KL of added reactor capacityCompleted
USFDA re-inspectionDisclosed 6 Feb 2026Zero Form 483 observationsCompleted
WHO-PQ for amodiaquine HCl2,026Opens SPAQ (seasonal malaria chemoprevention) institutional demandCompleted
EDQM CEP for sulfadimethoxine2,025EU market accessCompleted
EcoVadis Bronze medal2,026Supply-chain sustainability rating demanded by MNC customersAchieved
Pipeline: vonoprazan, pretomanid, edoxaban, bisoprolol (plus ticagrelor, linagliptin, pyronaridine, ethambutol per ICRA)2025–26Diversification away from mature macrolides and steroidsUnder development; no timelines disclosed
Marketing initiatives in regulated and unregulated markets; new CMO for regulated marketsFY26Per ICRA and senior-management rosterOngoing
Bonus issue 1:1Jul 2025Improves liquidity of a thinly traded stockCompleted
Revised governance policies (RPT, dividend distribution, materiality, NRC, fair-disclosure code)May 2025; revised RPT policy Aug 2026Regulatory alignmentCompleted
Japan approval ("Pharma Copia, Japan")Referenced in ICRA Jan 2025Approval sought from a Japanese counterpartyUnconfirmed status

No quantified emissions targets are disclosed.

Cost programmes with targets. None quantified publicly.

Medium-term guidance

Guidance itemStatementSource
Revenue growth"Steady" 15–20% per annum growth anticipatedFY26 deck (May 2026); Q1 FY27 deck (Aug 2026)
Margin targetsNot quantified—
CapexNo debt-funded capex planned in the near termICRA Sep 2025
DividendConsistent dividend record. A revised dividend distribution policy was adopted (May 2025); quantum not specified.Board outcome, May 2025

Implied check. 15–20% growth on FY26 revenue of INR 772 Cr implies FY27 revenue of INR 887–926 Cr. Q1 FY27 revenue of INR 193.8 Cr (+3.9%) means the remaining three quarters need about 20–25% YoY growth to hit the low end (derived).

Products & Services

All products sit within the single "Bulk drugs & chemicals" segment and are grouped below by therapeutic category, as in the company's portfolio slide.

Pricing. No list prices are disclosed for any product. APIs sell business-to-business at negotiated prices. Launch years for individual molecules are not disclosed except where the regulatory milestone date is a proxy.

Macrolides (erythromycin family) — flagship franchise

ProductDescription / useKey credentialsTarget customerMilestone year
Erythromycin baseMacrolide antibiotic APIEU GMP / CEP (2010)Generic formulators, EU and RoW1989 franchise start; CEP 2010
Erythromycin estolateOral salt (suspensions)COFEPRIS Mexico (2014)LatAm and RoW formulators2,014
Erythromycin stearateOral tablet saltCOFEPRIS (2014); UK MHRA DMF (2017)UK, EU, LatAm2,017
Erythromycin ethyl succinatePaediatric oral saltCEP/EU GMP (2010); COFEPRIS (2014)Global formulators2,010
Erythromycin propionateSalt form—RoW—
Erythromycin phosphateSalt form—RoW—
Erythromycin 11,12-carbonateDerivative / intermediate—Formulators / derivative makers—

The company claims to be India's largest erythromycin-salt producer and among the global top five (ICRA, Sep 2025). Erythromycin revenue was INR 241 Cr in FY26, about 31% of revenue.

Higher macrolides

ProductDescriptionCredentialsFY26 revenue
AzithromycinBroad-spectrum macrolideEDQM CEP (2023)INR 110 Cr (group), +62% YoY
RoxithromycinMacrolide (cited by ICRA as a portfolio product)—Included in group

Corticosteroids (15 molecules)

The portfolio comprises:

  • Beclomethasone dipropionate

  • Betamethasone acetate

  • Betamethasone dipropionate

  • Betamethasone sodium phosphate

  • Betamethasone valerate

  • Clobetasol propionate

  • Deflazacort

  • Dexamethasone sodium phosphate

  • Dexamethasone acetate

  • Mometasone furoate

  • Prednisolone acetate

  • Prednisolone sodium phosphate

  • Triamcinolone acetonide

  • Triamcinolone base

  • Methyl prednisolone

The flagship molecules, where the company claims leadership, are clobetasol propionate and betamethasone dipropionate. Group revenue was INR 82 Cr in FY26, down 20% YoY. The targets are topical, ophthalmic, injectable and oral steroid formulators. A secondary source also lists clobetasol butyrate, but this is not in the company's current portfolio slide.

Source: Q1 FY27 presentation; FY26 presentation summary.

Anti-tuberculosis

ProductCredentialsNotes
PyrazinamideCEP/EU GMP (2010); WHO-PQ (2012 per IIFL; 2019 per company timeline); EU GMP AEMPS (2019)Company claims world's largest producer (ICRA). FY26 revenue INR 42 Cr.
IsoniazidWHO-PQ (2024)Newer addition
PretomanidPipeline (under development)Next-generation anti-TB, used in BPaL-type regimens
EthambutolPipeline (ICRA list, Sep 2025)Completes a first-line TB "basket"

Anti-malarials

ProductCredentialsNotes
SulfadoxineWHO-PQ (2015, renewed 2019); EDQM CEP (2023)FY26 revenue INR 100 Cr (+11%). Q1 FY27 INR 37 Cr vs INR 11 Cr.
PyrimethamineWHO Geneva PQ (2019/2020)Partner molecule to sulfadoxine (SP combination)
Amodiaquine HClWHO-PQ (2026)Enables SPAQ seasonal malaria chemoprevention supply
Pyronaridine tetraphosphatePipeline (ICRA list)Artemisinin-combination partner drug

Anti-diabetics

ProductCredentialsNotes
GliclazideEDQM CEP (2023)FY26 revenue INR 21 Cr (-25%). Q1 FY27 INR 11.9 Cr vs INR 5.1 Cr.
Vildagliptin—DPP-4 inhibitor; off-patent in many markets
Dapagliflozin—SGLT2 inhibitor; generic opportunity as exclusivities lapse
LinagliptinPipeline (ICRA list)DPP-4 inhibitor

Anti-bacterials, antibiotics and quinolones

ProductCredentialsNotes
ChloramphenicolCOFEPRIS (2015)Q1 FY27 INR 4.0 Cr vs INR 12.2 Cr
Chloramphenicol palmitateCOFEPRIS (2015)Paediatric oral
Sulfadimethoxine (and sodium salt)EDQM CEP (2025)Sulfonamide; used heavily in veterinary medicine
Moxifloxacin—Fourth-generation fluoroquinolone

Respiratory, anti-allergy, anti-gout, others

ProductCategoryCredentials
Ambroxol HClExpectorant / mucolyticEDQM CEP (2024); claimed leadership. Q1 FY27 INR 7.9 Cr.
Acefylline piperazineBronchodilator / expectorant—
AcebrophyllineAnti-asthmatic—
Bilastine (listed as "Bilsatin")Antihistamine—
AllopurinolAnti-goutEDQM CEP (2024)

Development pipeline

MoleculeTherapy areaSourceStatus
Vonoprazan fumarateAnti-ulcer (potassium-competitive acid blocker)Q1 FY27 and FY26 presentations; ICRAUnder development
PretomanidAnti-TBQ1 FY27 presentationUnder development
Edoxaban tosylateAnti-coagulant (factor Xa inhibitor)Q1 FY27 presentationUnder development
Bisoprolol fumarateBeta-blocker / anti-hypertensiveQ1 FY27 presentationUnder development (added Aug 2026)
TicagrelorAnti-plateletICRA Sep 2025Development stage
LinagliptinAnti-diabeticICRA Sep 2025Development stage
Pyronaridine tetraphosphateAnti-malarialICRA Sep 2025Development stage
EthambutolAnti-TBICRA Sep 2025Development stage
Sulfadimethoxine sodiumAntibioticICRA Sep 2025CEP received 2025

Services: none. The company does not disclose any contract development and manufacturing (CDMO) or custom-synthesis business.

Financial Narrative

Data notes

  • Revenue from operations and PAT for FY24–FY26 come from audited exchange filings.

  • FY22–FY23 lines and the gross-profit, EBIT and cash-flow lines come from S&P Global Market Intelligence via StockAnalysis.com (in INR mn), converted to INR Cr.

EBITDA is shown on two bases: - (a) the company's definition, which includes other income and is reported in results notes and the investor deck;

  • (b) S&P's definition, which is EBIT plus D&A and excludes non-operating items.

  • The FY26 investor deck's five-year chart shows FY26 PAT as 47.4. That conflicts with the audited FY26 PAT of INR 41.05 Cr and appears to be a typographical repetition of FY25. The audited figure is used here.

  • Total revenue (including other income) was INR 776.0 Cr in FY26. This explains the 15.66% growth rate cited in management commentary, against 16.65% on revenue from operations.

Income statement

Sources: FY24–FY26 audited results (BSE/NSE); FY22–FY26 investor deck five-year track record; StockAnalysis/S&P income statement (updated 7 Aug 2026).

Per-share data (INR, adjusted for the 1:1 bonus of July 2025):

Notes:

  • FY25 EPS was reported as INR 9.45 pre-bonus (FY25 audited results); the Q3 FY26 filing restates it to INR 4.72.

  • The FY24 dividend was INR 2.50 on pre-bonus shares (50% of face value), equal to INR 1.25 adjusted.

  • The FY25 and FY26 dividends were INR 1.50 on post-bonus shares (30% of face value).

  • There are no dilutive instruments, so basic and diluted EPS are identical.

Sources: StockAnalysis/S&P; board outcomes, May 2025 and May 2026.

Margins:

FY24–FY26 company EBITDA margins are as reported. FY22–FY23 are derived (company EBITDA divided by revenue from operations). Gross, EBIT and net margins are from S&P.

Growth:

  • Revenue CAGR FY22–FY26 (revenue from operations): 12.2% (derived: 771.7 / 486.6 over 4 years).

  • PAT CAGR FY22–FY26: 7.7% (derived).

  • EPS CAGR FY22–FY26: 7.7%.

  • Dividend-per-share CAGR FY22–FY26: 14.4% (derived).

Commentary. FY24 was the cyclical high. Revenue grew 22.7%, EBITDA margin reached 13.5%, and PAT rose 66% to INR 60.1 Cr. Two things drove it: the 1,800 MTPA capacity step-up and favourable realisations. Large mark-to-market and realised gains on mutual-fund investments also helped, at INR 10.7 Cr of investment gains (S&P).

FY25 was flat. Revenue grew 2.2%, while EBITDA margin fell to 10.6% and PAT fell 21% to INR 47.4 Cr. ICRA attributes this to price erosion in commoditised products, which offset volume growth.

FY26 brought the best volume growth in the period: production rose 25% to 1,733 MT and revenue grew 16.7%. Profit nonetheless fell again, by 13.3% to INR 41.0 Cr, for four reasons:

  • Gross margin compressed by about 230 bp, as cost of materials rose faster than revenue and trading mix increased (purchases of stock-in-trade doubled to INR 79.2 Cr).

  • Foreign-exchange losses rose to INR 6.1 Cr from INR 2.8 Cr (S&P).

  • Investment gains fell (INR 3.6 Cr vs INR 7.8 Cr).

  • Depreciation rose about 30% after the FY25 capex.

FY26 was therefore growth without operating leverage. The inflection appears to have come in H2 FY26 (Q3 EBITDA margin 10.6%) and was confirmed in Q1 FY27 (9.99% vs 7.34%).

Quarterly trajectory

Sources: FY25 audited results (Q3–Q4 FY25); Q3 FY26 results (Q2–Q3 FY26); Q1 FY27 results and presentation (Q4 FY26, Q1 FY26, Q1 FY27).

Notes:

  • The quarterly PATs for FY26 sum to INR 41.04 Cr, which reconciles to the audited annual figure.

  • Adjusted EBITDA, which excludes forex and mutual-fund mark-to-market, was 12.18% in Q3 FY26 and 9.26% for 9M FY26 (Q3 FY26 results, note 3).

  • Q4 FY26 EBITDA excluding other items was INR 23.56 Cr, down 18.3% YoY, on flat production of 426 MT (FY26 deck, Joint MD message).

Balance sheet

Sources: StockAnalysis/S&P balance sheet (updated 7 Aug 2026); FY25 audited statement of assets and liabilities (INR lakh).

Notes:

  • The FY25 short-term debt of INR 10.5 Cr was a stand-by letter of credit, not a term loan (ICRA, Sep 2025).

  • There is no goodwill.

  • Long-term debt other than leases is nil throughout.

  • The company's own balance sheet shows FY25 total investments (current and non-current) of INR 105.8 Cr, falling to INR 39.6 Cr non-current at FY26 (board outcome, May 2026). S&P classifies these differently, so cash figures vary by source.

Commentary. Equity grew at an 11.9% CAGR, entirely from retained earnings. The bonus capitalised INR 25.1 Cr of general reserve into share capital without changing net worth.

The critical change in FY26 was inventory, which doubled to INR 147.8 Cr from INR 74.5 Cr. Together with higher receivables, this lifted working capital by INR 50.6 Cr. It was funded by running down liquid investments, about INR 25 Cr net sold according to the S&P cash-flow line, and by stretching payables by INR 31 Cr. Whether the build is strategic stocking for regulated-market launches or a demand mismatch is the key unanswered question. Q1 FY27 shows a further inventory build of INR 15.8 Cr (change in inventories, Q1 FY27 results).

Cash flow

Sources: StockAnalysis/S&P cash-flow statement. The FY24 and FY25 operating cash flow and capex reconcile to the company's audited FY25 cash-flow statement (INR 1,292.52 lakh and INR 3,712.48 lakh operating cash flow; INR 1,996.29 lakh FY25 capex on PP&E).

Commentary. Cumulative FY22–FY26 FCF was about INR 94 Cr, against cumulative PAT of about INR 215 Cr. That is a FCF-to-PAT conversion of roughly 44%. Working-capital absorption explains the gap; capex does not, since cumulative capex was only about INR 36 Cr.

FY26 FCF was negative for the first time in the period. Dividends have been paid from balance-sheet liquidity rather than free cash flow in two of the last three years (FY24 and FY26).

Capex is unusually low for an API maker of this size, at about 1% of revenue in FY26. Capacity additions have been "brownfield debottlenecking": 40 KL of reactors added for the 2,200 to 2,400 MTPA step (FY26 directors' report).

Ratios

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Segment Revenue

Reported segmentContentsRevenue FY26 (INR Cr)Share of revenueSegment PBT FY26 (INR Cr)

Bulk drugs & chemicals

All APIs, intermediates and traded goods

771.66100%54.22

Revenue by Segment

Product group (INR Cr)FY2025FY2026

Erythromycin salts

221241

Higher macrolides (azithromycin)

68110

Sulphadoxine

90100

Corticosteroids

10282

Pyrazinamide

3842

Gliclazide

2821

Other items

58110

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Segment Revenue (% of FY26 revenue from operations (771.66)–YoY growth FY26)

Product groupYoY growth FY26% of FY26 revenue from operations (771.66)

Erythromycin salts

+9.0%31.2%

Higher macrolides

+61.8%14.3%

Sulphadoxine

+11.1%13.0%

Corticosteroids

-19.6%10.6%

Pyrazinamide

+10.5%5.4%

Gliclazide

-25.0%2.7%

Other items

+89.7%14.3%

Revenue by Segment (Quarterly)

Product group (INR Cr)Q1FY2026Q1FY2027

Erythromycin

63.649.1

Higher macrolides

19.739.9

Sulphadoxine

11.037.0

Corticosteroids

20.920.1

Pyrazinamide

10.312.2

Gliclazide

5.111.9

Other items

34.710.9

Ambroxol HCl

8.47.9

Chloramphenicol

12.24.0

Results by Segment and Segment Margins & Growth (%)

MetricFY2025FY2026

Revenue from operations (INR Cr)

661.51771.66

EBITDA incl. other income (INR Cr)

70.3666.08

EBITDA margin (%)

10.648.56

PBT (INR Cr)

61.0154.22

PBT margin (%)

9.227.03

Income Statement

Metric (INR Cr)FY2022FY2023FY2024FY2025FY2026

Revenue from operations

486.6527.5647.0661.5771.7

Total revenue incl. other income (company)

491.8537.0659.0671.0776.0

Gross profit (S&P)

105.7120.0155.6154.8163.1

Operating income / EBIT (S&P)

36.543.766.955.056.5

EBITDA (company basis, incl. other income)

52.057.487.270.466.1

EBITDA (S&P basis)

48.253.174.963.267.3

Depreciation & amortisation (S&P)

11.99.68.58.611.3

Pre-tax income

39.147.578.361.054.2

Income tax

8.611.318.313.713.2

Net income (PAT)

30.636.260.147.441.0

Per-Share Data

Metric (INR per share)FY2022FY2023FY2024FY2025FY2026

EPS basic

3.053.615.994.724.10

EPS diluted

3.053.615.994.724.10

Dividend per share

0.8751.001.251.501.50

Margin (%)

Margin (%)FY2022FY2023FY2024FY2025FY2026

Gross margin

21.7222.7424.0523.4021.13

Operating (EBIT) margin

7.518.2910.348.317.32

EBITDA margin (company basis)

10.6910.8813.4810.648.56

Net margin

6.286.869.287.165.32

Income Statement and Margin Analysis (%)

Metric (INR Cr)Q3FY2025Q4FY2025Q1FY2026Q2FY2026Q3FY2026Q4FY2026Q1FY2027

Revenue from operations

159.5198.1186.5185.9197.2202.1193.8

EBITDA (company basis)

15.720.113.712.920.918.619.4

EBITDA margin %

9.8610.137.346.9210.609.229.99

PBT

13.317.311.09.917.815.516.9

PAT

10.312.58.37.613.511.711.4

EPS (INR, adjusted)

1.031.250.830.761.341.171.14

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Balance Sheet and Per-Share Data

Metric (INR Cr)FY2022FY2023FY2024FY2025FY2026

Total assets

347.2405.0445.7506.6557.4

Cash & short-term investments

25.353.162.373.452.9

Long-term investments

21.239.751.762.039.6

Trade receivables

135.7171.2189.9215.9238.6

Inventory

79.972.675.474.5147.8

Net PP&E

61.352.749.258.456.1

Trade payables

121.6152.8140.5156.8187.7

Short-term borrowings

3.10.02.010.50.0

Lease liabilities (current + non-current)

1.10.90.70.40.1

Total debt

4.20.92.710.90.1

Net debt (negative = net cash; excl. LT investments)

-21.0-52.2-59.6-62.5-52.9

Shareholders' equity

213.8241.2291.2326.0352.2

Goodwill & intangibles

0.20.10.20.10.5

Working capital

127.8146.3185.8197.7248.3

Book value per share (INR)

21.3324.0729.0632.5335.14

Cash Flow

Metric (INR Cr)FY2022FY2023FY2024FY2025FY2026

Operating cash flow

28.953.912.937.1-3.0

Capital expenditure

1.61.65.020.17.9

Free cash flow

27.252.47.917.0-10.9

Dividends paid

7.68.710.012.515.0

Share buybacks

00000

Change in working capital

-9.316.4-43.6-13.1-54.9

Cash taxes paid

9.113.519.111.113.2

Returns & Leverage Ratios (%) and Financial Ratios (x)

RatioFY2022FY2023FY2024FY2025FY2026

ROE % (on average equity; FY22 on closing equity)

14.315.922.615.312.1

ROA % (on average assets; FY22 on closing assets)

8.89.614.19.97.7

ROCE % (Screener)

1819261716

Current ratio (x, company)

1.981.912.202.112.22

Debt / equity (x, company)

0.010.000.010.030.00

Net debt / EBITDA (x, company EBITDA; negative = net cash)

-0.40-0.91-0.68-0.89-0.80

Interest coverage (EBIT / interest, x, derived)

3820018989120

Asset turnover (x)

1.401.401.521.391.45

Cash conversion cycle (days, company)

5856617286

Revenue by Region

Region (INR Cr)FY2025FY2026

Domestic (India)

297417

Export

365355

Growth / share

Growth / shareFY2026

Domestic growth YoY

+40.4%

Export growth YoY

-2.7%

Export share of revenue

46% (company: "~46%")

Revenue by Region (Quarterly)

Region (INR Cr)Q1FY2026Q1FY2027

Domestic

98124

Export

8870

Revenue by Region (%)

Region (% of exports)Q1FY2026Q1FY2027

Asia

26.835.7

Europe

35.529.6

Africa

30.927.9

North America

3.84.2

Latin America

3.12.6

Revenue by Region (%) by Customer Concentration

Customer concentration (%)Q1FY2026Q1FY2027

Top 5 share of export sales

3730

Top 5 share of domestic sales

5534

Top 5 share of total sales

3620

Valuation Snapshot

MetricValueDate / source

Last price

INR 83.05 (BSE close)

16 Oct 2026, StockAnalysis/S&P

52-week range

INR 66.72 – 99.50

Anand Rathi (Sep 2026)

52-week price change

+5.35%

S&P, 19 Oct 2026

50-day / 200-day moving average

INR 84.39 / INR 79.67

S&P

Beta (5Y)

0.48

S&P

Average daily volume (20D)

About 13,400 shares

S&P

Market cap / EV

INR 832 Cr / INR 779 Cr

S&P

Return period

Return periodValue (measured 22 Sep 2026, price INR 93.49)Value (measured 28 Aug 2026, price INR 83.57)

1-year

+8.9%-4.5%

3-year

+45.6%+25.0%

5-year

+58.4%+39.1%

Valuation Multiples

MultipleAnuh Pharma

P/E (TTM EPS INR 4.40)

18.85x

EV/EBITDA (S&P EBITDA)

10.47x

EV/Sales

1.00x

P/B (BVPS INR 35.14)

2.36x

EV/EBIT

12.46x

Dividend yield

1.81%

Earnings yield / FCF yield

5.31% / -1.31%

Dividend (INR per share, adjusted)

Dividend (INR per share, adjusted)FY2022FY2023FY2024FY2025FY2026

Dividend per share

0.8751.001.251.501.50

Dividend outflow (INR Cr, company)

8.7710.0212.5315.0315.03

Payout ratio % (Screener)

2928211637

Credit Ratings

AgencyInstrumentRatingOutlookDate

ICRA

Long-term fund-based (CC/WCDL, interchangeable; INR 5 Cr sub-limit)

[ICRA]A-

Positive

15 Sep 2025

ICRA

Short-term (export credit, INR 60 Cr sub-limit; LC/SBLC/buyer's credit INR 90 Cr)

[ICRA]A2+

—

15 Sep 2025

ICRA

Long/short-term interchangeable (bank guarantee, INR 90 Cr sub-limit)

[ICRA]A- (Positive) / [ICRA]A2+

Positive

15 Sep 2025

Moody's / S&P / Fitch

—

Not rated

——

Analyst Conclusions

Management guidance

Revenue: "steady" growth of 15–20% per annum, reiterated in the May 2026 and August 2026 decks. That implies FY27 revenue of roughly INR 887–926 Cr (derived).

Drivers cited: regulated-market expansion after the USFDA and EU GMP clearances, product-mix enrichment, cost control and better throughput.

No guidance: on margins, capex quantum or dividends.

Consensus

No sell-side consensus exists. The market-implied view is that a P/E of about 19x and EV/EBITDA of about 10.5x price in modest growth and a partial margin recovery.

Bull case

  1. Margin mean-reversion is under way. EBITDA margin recovered from 6.92% (Q2 FY26) to 10.60% (Q3), 9.22% (Q4) and 9.99% (Q1 FY27). Q1 FY27 ROCE was 19.18%, against 15.92% for FY26. If FY27 EBITDA margins hold at about 10% on 15% growth, EBITDA would be about INR 89 Cr, a new high (derived).

  2. Regulatory optionality is cheap. A zero-483 USFDA outcome (2026), new WHO-PQ (amodiaquine) and new CEPs give access to US, EU and institutional markets. North America is still only about 4% of exports, so even modest US wins would be material for a company valued at about INR 830 Cr.

  3. The balance sheet funds growth and payouts. About INR 90 Cr of cash and investments, no debt, and capex of only INR 8–20 Cr a year mean the company can absorb working-capital build, sustain the INR 1.50 dividend, and pursue backward integration without dilution. ICRA's Positive outlook offers an upgrade path.

Bear case

  1. Growth without profit has persisted. FY26 revenue rose 16.7% while PAT fell 13.3%. Cumulative FY22–FY26 FCF covered only about 44% of PAT. Q1 FY27 revenue grew just 3.9%, making the 15–20% target already stretched.

  2. Working capital is consuming the business. The cash conversion cycle rose to 86 days and inventory doubled. If the inventory build reflects slow-moving stock rather than pre-launch stocking, write-downs or price-cutting would follow.

  3. The commodity trap and concentration. About 31% of revenue comes from erythromycin, which fell 23% YoY in Q1 FY27. Exports appear to have declined YoY in Q1 FY27 (on the reconciling reading). All production is at one site. ICRA's 7% margin floor was breached in Q2 FY26, so another weak quarter could hit the rating outlook.

Catalysts and monitorables (next 12 months)

TimingCatalyst / monitorable
About 13 Nov 2026Q2 FY27 results. Can margin stay near 10% while growth rebounds toward 15%+?
Q2–Q3 FY27Inventory and receivables trend; whether the cash conversion cycle reverts toward 60–70 days
Q3 FY27Export trajectory, Europe and North America in particular; first US commercial supplies after the USFDA inspection
Through FY27Regulatory filings and approvals for pipeline molecules (vonoprazan, edoxaban, pretomanid, bisoprolol, ticagrelor)
Through FY27WHO-linked tender wins in anti-malarials and anti-TB (sulfadoxine/amodiaquine, pyrazinamide/isoniazid)
Around Sep 2026 – early 2027ICRA surveillance: possible upgrade to A or reversion to Stable
FY27Capital allocation: use of surplus treasury (capex, backward integration, a second site) and the dividend decision (May 2027)
OngoingPromoter-group actions (reclassification, holding changes) and related-party transactions under the revised RPT policy

Analyst verdict

Anuh Pharma is a well-run, conservatively financed, but structurally low-return API converter. It is trying to climb the value chain, and the evidence of the past three years points in two directions at once.

On the operating side, the company has done what a small API maker must do to earn the right to grow. It added capacity cheaply, from 1,800 to 2,400 MTPA, and lifted production by a quarter in FY26. It also widened its regulatory perimeter: a clean USFDA inspection, fresh CEPs and a new WHO pre-qualification. The Q1 FY27 numbers suggest mix is finally helping. Sulphadoxine, higher macrolides and gliclazide are replacing low-margin trading and weaker erythromycin, and EBITDA margin has recovered to about 10%.

On the financial side, three years of evidence point the other way. Gross margins remain in the low twenties, profits are below their FY24 peak, and working capital is absorbing most of the earnings. FY26 produced negative operating cash flow even as revenue reached a record. The 15–20% growth guidance looks ambitious against a Q1 that grew under 4%. The company also discloses too little on R&D, export customers and the inventory build for investors to judge whether the new pipeline will change the economics.

At about 19x trailing earnings and about 10.5x EV/EBITDA, the stock is not demanding for a net-cash company with ICRA A- (Positive) credit and a five-year dividend-growth record. Nor does it price much failure.

The investment case reduces to one testable proposition: can Anuh hold about 10% EBITDA margins while converting its regulatory credentials into above-15% growth and reversing the cash-conversion slippage? Q2 and Q3 FY27 results will largely answer it.

Until then, the balance of evidence supports a neutral-to-constructive stance. Downside is cushioned by the balance sheet and dividend. Upside depends on execution evidence that has only just begun to appear.


APPENDIX — SOURCES

  1. Anuh Pharma, Investor Presentation Q1 FY2026-27 (NSE filing, 19 Aug 2026) — nsearchives.nseindia.com/corporate/ANUHNSE_19082026165402_Intimation_for_investor_presentation.pdf

  2. Anuh Pharma, Unaudited Financial Results Q1 FY27 (NSE filing, 7 Aug 2026) — nsearchives.nseindia.com/corporate/ANUHNSE_07082026181608_Financials.pdf

  3. Anuh Pharma, Outcome of Board Meeting and FY26 Audited Results (NSE filing, 20 May 2026) — nsearchives.nseindia.com/corporate/ANUHNSE_20052026230618_Outcome_of_Board_Meeting.pdf

  4. Anuh Pharma, Unaudited Results Q3 FY26 (BSE filing, 6 Feb 2026) — bsmedia.business-standard.com (announcement bd82a7c8)

  5. Anuh Pharma, Reg. 30 USFDA inspection disclosure (6 Feb 2026) — bsmedia.business-standard.com (announcement 1e41ffca)

  6. Anuh Pharma, Outcome of Board Meeting and FY25 Audited Results (23 May 2025) — bsmedia.business-standard.com (announcement 1fe6019a)

  7. Anuh Pharma, Investor Presentation Q2 FY2025-26 (NSE filing, 17 Nov 2025)

  8. NSE Circular NSE/CML/69079 — Listing of bonus shares (11 Jul 2025)

  9. Anuh Pharma, Withdrawal of NSE direct listing application (BSE filing, 10 Mar 2022)

  10. ICRA, Anuh Pharma Limited: Ratings reaffirmed (15 Sep 2025) — icra.in rationale 137612

  11. ICRA rationales: Jan 2025 (outlook to Positive), Dec 2023, Aug 2021, Oct 2020, Aug 2018

  12. Multibagg AI, "Anuh Pharma FY2026: Strong growth, tighter margins" (30 May 2026)

  13. StockAnalysis.com (S&P Global Market Intelligence data) — income statement, balance sheet, cash flow, statistics for BOM:506260 / NSE:ANUHPHR (accessed Oct 2026)

  14. Screener.in — Anuh Pharma company pages (accessed 2025–2026)

  15. Indian Pharma Post, "Anuh Pharma PAT grew 37.63% to Rs. 11.42 crore in Q1 FY27" (19 Aug 2026)

  16. Sahi.com, Anuh Pharma Q1 FY27 and growth-guidance coverage (Aug 2026)

  17. Quartr, Anuh Pharma Q1 FY26-27 earnings summary (Aug 2026)

  18. IIFL / IndiaInfoline — Anuh Pharma directors' report FY26 and company summary (2026)

  19. Pharma Now, "USFDA Completes Inspection of Anuh Pharma's Facilities Without Form 483 Observation" (9 Feb 2026)

  20. Medical Dialogues / DSIJ — 2019 USFDA inspection coverage (Sep 2019)

  21. Anand Rathi, Upstox, Kotak Neo, Finology, IndMoney, Research360, MarketsMojo — share price and return data (2025–2026)

  22. Ipca Laboratories, NSE filing on Tarapur USFDA inspection (5 Dec 2025) — industry context

  23. Aarti Drugs FY26 results — Indian Pharma Post (19 May 2026); FilingReader (16 May 2026); Quartr AGM 2026 summary; Anand Rathi financials

  24. Supriya Lifescience FY26 results — Indian Pharma Post; Arihant Capital (May 2026)

  25. Aarti Pharmalabs FY26 results — Trendlyne summary (May 2026)

  26. Anuh Pharma 56th Annual Report FY2015-16 (BSE) — historical context

  27. RegisterKaro / MCA-derived company data — incorporation details

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Board of Directors

NameRoleTenure / appointmentBackgroundAgeSource

Arun Todarwal

Chairman

Not disclosed. Named among directors retiring by rotation at the 66th AGM (FY26 directors' report), which implies non-independent status; independence classification not confirmed.

Fellow of ICAI, in practice since 1981. Director of several large listed companies, serving on audit, risk, nomination-and-remuneration and ESG/CSR committees.

—

Q1 FY27 presentation; FY26 directors' report

Bipin N. Shah

Vice Chairman (Promoter)

With Anuh since inception as MD

Bachelor's in Chemical Engineering; President of the Thane Belapur Industries Association

—

Q1 FY27 presentation

Ritesh B. Shah

Joint Managing Director (Promoter)

Reappointed for 5 years from 8 Jan 2026 to 7 Jan 2031

BSc Chemistry, MBA. Led international marketing for over 20 years; marketing, finance, strategy and sourcing. Son of Bipin Shah.

44 (May 2025)

Board outcome, May 2025

Vivek B. Shah

Joint Managing Director (Promoter)

Reappointed for 5 years from 8 Jan 2026 to 7 Jan 2031

MSc Biotechnology. Has led manufacturing and R&D since 2009; operations, R&D and regulatory affairs. Son of Bipin Shah.

—

Board outcome, May 2025

Bharat N. Shah

Non-executive, non-independent director

Reappointed on rotation, 22 Aug 2025

About five decades in pharma across SK Group formulations, APIs, exports and R&D. Brother of Bipin Shah.

—

Board outcome, May 2025

Gaurav S. Shah

Non-executive, non-independent director

Reappointed on rotation, 22 Aug 2025

BE (Computers, USA); NMIMS diploma in family-managed business; 20 years in formulations, APIs and logistics. Nephew of Bipin Shah.

—

Board outcome, May 2025

Independent directors

—

Names and number not identified in sources reviewed

———

“—” = not publicly disclosed.

Executive Leadership Team

NameTitleBackground

Raju Kotadia

Chief Marketing Officer — Emerging Markets

BSc Chemistry; with Anuh since inception; overall sales management

Vinayak Shenoy

Chief Marketing Officer — "MM" (regulated markets inferred)

MBA Marketing; 15+ years in APIs and intermediates across the USA, Europe, CIS, SE Asia, LatAm and India

Sanjay Barhate

VP Quality

MSc, MPhil Chemistry; 34 years in plant and corporate quality

Darshan Rampariya

Chief Financial Officer (and investor contact)

Chartered Accountant; 17+ years in audit, tax, finance and investor relations

Manan Vadhan

Company Secretary & Compliance Officer

ACS; 4+ years in secretarial compliance

Dr. Sanjay Vaidya

GM R&D

25 years in industrial process research on API molecules

Gulshan Sharma

GM Works

BTech (Chemical & Pharmaceutical); 21+ years in API and food industries

Board & Management Changes

DateChangeContext

23 May 2025

Joint MDs Ritesh and Vivek Shah reappointed (effective 8 Jan 2026)

Continuity of second-generation family leadership

22 Aug 2025

Bharat N. Shah and Gaurav S. Shah reappointed on rotation

Routine

Q2 FY26 (Jul–Sep 2025)

A "leadership addition" is noted in an aggregator summary of the Q2 FY26 filing; the role appears to be a senior marketing hire

Unconfirmed. Vinayak Shenoy (CMO-MM) appears in later decks.

Aug 2026

Arun Todarwal, among others, retires by rotation and is eligible for reappointment at the 66th AGM

Routine

Major Shareholders

Holder categoryStakeDateSource

Promoter & promoter group

71.80%

10 Aug 2026

Q1 FY27 presentation

Public (non-promoter)

28.20%

10 Aug 2026

Q1 FY27 presentation

Institutions (FII + DII)

About 0%

Jun 2026

StockAnalysis/S&P; Craytheon (DII 0.0%)

Insiders (S&P definition)

72.67%

Oct 2026

StockAnalysis/S&P

Promoter pledge

Zero

May 2026

Research360

Competitive Landscape

Competitor Detail

FranchiseNamed competitors (India / global)Notes

Erythromycin salts and macrolides

Chinese fermentation-integrated erythromycin and macrolide producers (the dominant source of erythromycin thiocyanate); Indian macrolide API makers such as Alembic Pharmaceuticals, Aurobindo Pharma and Hetero (azithromycin/clarithromycin)

Anuh claims India #1 and global top-5 in erythromycin salts (ICRA). It depends on fermentation-based upstream supply.

Corticosteroids

Symbiotec Pharmalab (India, private); Chinese steroid API producers; European steroid specialists

Price-competitive; Anuh's steroid revenue fell 20% in FY26

Anti-TB (pyrazinamide, isoniazid, ethambutol)

Lupin (historically a major anti-TB API maker); Chinese producers; Macleods (formulations-focused)

Anuh claims the world's largest pyrazinamide production

Anti-malarials (sulfadoxine, pyrimethamine, amodiaquine)

Ipca Laboratories (major anti-malarial API producer); Mangalam Drugs & Organics; Chinese producers

WHO-PQ is an entry barrier

Anti-diabetics (gliclazide, DPP-4, SGLT2)

Aarti Drugs; many Indian API makers entering gliptins and gliflozins

Crowded generic space

Chloramphenicol / sulfonamides

Chinese producers; smaller Indian producers

Commodity

Diversified mid-cap API peers (benchmarks)

Aarti Drugs, Supriya Lifescience, Aarti Pharmalabs, IOL Chemicals & Pharmaceuticals, Solara Active Pharma Sciences, Shilpa Medicare

Capital-markets peer set

Peer Comparison FY2026

MetricAnuh PharmaAarti DrugsSupriya LifescienceAarti Pharmalabs

FY26 revenue (INR Cr)

771.7

2,567.7 (consolidated)

827.9 (consolidated)

1,819.4 (consolidated)

Revenue growth YoY

+16.7%+7%+18.9%-14.0%

EBITDA margin

8.6% (company basis)

12.1%35.5%—

PAT (INR Cr)

41.0194.9209.1

174.7 (consolidated)

PAT margin

5.3%7.6%25.3%

about 9.6% (derived)

Export share of revenue

about 46%

about 38%

about 82%

—

ROCE

15.9% (FY26)

11.5% (FY26)

——

Company Snapshot

$89.1M

Revenue

323

Employees

1960

Founded

Mumbai, India

Headquarters

SWOT Analysis

Strengths

  • Clean regulatory record at the only site. USFDA inspections in Sep 2019 and early 2026 both closed with zero Form 483 observations (BSE filing, Sep 2019; Reg. 30 disclosure, 6 Feb 2026).
  • Breadth of approvals. CEPs cover erythromycin, pyrazinamide, sulphadoxine, azithromycin, gliclazide, allopurinol, ambroxol and sulfadimethoxine; WHO-PQ covers pyrazinamide, sulfadoxine, pyrimethamine, isoniazid and amodiaquine (Q1 FY27 presentation).
  • Category leadership. India #1 and global top-5 in erythromycin salts; world #1 in pyrazinamide (ICRA, Sep 2025, citing the company).
  • Fortress balance sheet. Debt-to-equity of 0.00 at FY26; about INR 53 Cr of cash and short-term investments plus about INR 40 Cr of long-term investments; interest coverage of 51.8x in FY25 (ICRA).
  • Dividend record. Dividend per share rose from INR 0.875 to INR 1.50 between FY22 and FY26 (adjusted), five consecutive years of growth (S&P). FY26 payout ratio was about 37%.
  • Volume momentum. Production rose 25% to 1,733 MT in FY26 and 19.5% in Q1 FY27 to 491 MT (FY26 and Q1 FY27 decks).

Weaknesses

  • Thin and falling margins. EBITDA margin fell from 13.48% (FY24) to 10.64% (FY25) to 8.56% (FY26). Gross margin was 21.1% in FY26 (company; S&P).
  • Working-capital deterioration. The cash conversion cycle widened from 56 days (FY23) to 86 days (FY26). Inventory doubled to INR 147.8 Cr, and operating cash flow was -INR 3.0 Cr in FY26.
  • Single-site risk. All 2,400 MTPA sits at Tarapur (ICRA, Sep 2025).
  • Product concentration. Erythromycin was about 31% of FY26 revenue; ICRA put erythromycin salts at about 32–33% of revenue (Jan 2025).
  • Sub-scale R&D. 16 scientists, with R&D spend not separately disclosed (FY26 deck).
  • No institutional ownership and thin float. Institutions hold about 0%; free-float market cap is about INR 220 Cr; 20-day average volume is about 13,400 shares (S&P; Q1 FY27 deck).

Opportunities

  • US market entry. The 2026 USFDA clearance supports DMF-backed supply to US generic makers. North America is only about 4–5% of exports today (Q1 FY27 deck).
  • WHO global-health APIs. Amodiaquine WHO-PQ (2026) complements sulfadoxine and pyrimethamine for SPAQ. Sulfadoxine revenue was INR 37 Cr in Q1 FY27 against INR 11 Cr a year earlier.
  • Pipeline of newer molecules. Vonoprazan, edoxaban, ticagrelor, linagliptin, pretomanid and bisoprolol (Q1 FY27 deck; ICRA).
  • Spare capacity. About 18–26% headroom at 2,400 MTPA (derived from the FY26 and Q1 FY27 production run-rates).
  • Deploying idle liquidity. About INR 90 Cr of cash and investments could fund backward integration or a second site without debt (FY26 balance sheet).
  • Mix improvement. Q1 FY27 EBITDA margin rose 265 bp on the product mix (Q1 FY27 deck).

Threats

  • Chinese price competition in commoditised molecules, which ICRA identifies as the main constraint on margins (Sep 2025).
  • Upstream supply concentration for erythromycin thiocyanate and steroid intermediates. Not quantified by the company; independent assessment.
  • Regulatory reversal risk. A certification suspension in FY2017 caused revenue to fall about 37% (from INR 326 Cr to INR 206 Cr; Screener).
  • Forex volatility. FY26 forex loss of INR 6.1 Cr against INR 2.8 Cr in FY25 (S&P).
  • Rating-trigger proximity. ICRA would move the outlook to Stable or lower the rating if operating margins stay below 7%. Q1 and Q2 FY26 EBITDA margins were 7.34% and 6.92%.
  • Peer capacity additions. Aarti Drugs' new Sayakha facility reached about 1,000 tonnes per month by March 2026 (Aarti Drugs FY26 results), adding to industry supply in overlapping anti-diabetic and anti-infective APIs.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
23 May 2025FY25 audited results: revenue from operations INR 661.5 Cr (+2.2%), PAT INR 47.4 Cr (-21%), EBITDA margin 10.64% (13.48% in FY24)Confirms a margin down-cycle
23 May 2025Board recommends a 1:1 bonus, INR 1.50 dividend on post-bonus capital, reappointment of both Joint MDs to 2031, a new secretarial auditor (GHV & Co.), and revised governance policiesShareholder-friendly; continuity of governance
Q2 FY26 (Jul 2025)Shareholders approve the bonus via postal ballotCorporate action
11 Jul 2025NSE circular admits 50,112,000 bonus shares from 17 Jul 2025Liquidity
15 Jul 2025Capacity enhanced to 2,400 MTPA (40 KL of reactors) at Tarapur; bonus record dateCapacity +9%
16 Jul 2025Bonus allotment; share capital doubles to INR 50.1 CrCorporate action
8 Aug 2025Q1 FY26: revenue INR 186.5 Cr (+35% YoY per ICRA), PAT INR 8.3 Cr, EBITDA margin 7.34%Volume-led growth but margin trough
22 Aug 202565th AGM: dividend INR 1.50 approved; directors reappointed; JMD remuneration revisedRoutine
15 Sep 2025ICRA reaffirms [ICRA]A- (Positive)/A2+ on INR 90 Cr of facilities. Names the 7% operating-margin floor as a downgrade trigger, and new-product ramp-up as the key monitorable.Credit stability
26 Sep 2025Notice of transfer to IEPF of shares with dividends unclaimed for seven years. During FY26, INR 2.0 lakh of unclaimed dividends and 24,340 shares were transferred.Routine compliance
7 Nov 2025Q2 FY26: revenue INR 185.9 Cr, PAT INR 7.6 Cr, EBITDA margin 6.92%; a leadership addition reported (details unconfirmed)Weakest margin quarter in the dataset
17 Nov 2025Q2 FY26 investor presentation filedDisclosure
21 Nov 2025New Labour Codes take effect; the company books a one-off INR 48.31 lakh past-service obligation in Q3 FY26Minor one-off cost
6 Feb 2026Q3 FY26: revenue INR 197.2 Cr (+24% YoY), PAT INR 13.45 Cr (+30%), EBITDA margin 10.60% (adjusted 12.18%)Margin inflection
6 Feb 2026USFDA inspection of the Tarapur facilities completed with no Form 483 observationsMajor regulatory de-risking; opens the US
2026 (date not specified)WHO-PQ for amodiaquine HClExpands anti-malarial basket (SPAQ)
2026 (date not specified)EcoVadis Bronze medalESG credential for MNC supply chains
20 May 2026FY26 audited results: revenue from operations INR 771.7 Cr (+16.7%), PAT INR 41.0 Cr (-13.3%), PBT -11%; INR 1.50 dividend recommended; promoter-group reclassification requests placed before the boardGrowth without profit; governance item
20 May 2026Q4 FY26: revenue INR 202.1 Cr (+2.0% YoY), PAT INR 11.7 Cr (-6.3% YoY); EBITDA excluding other items down 18% YoY; other income negativeGlobal market challenges cited, not quantified
28 May 2026FY26 investor presentation: production 1,733 MT (+25%); 15–20% growth guidance; pipeline disclosed; cash conversion cycle 86 daysStrategy and guidance
29 May 2026FY26 annual secretarial compliance report filed; waiver of a past BSE fine of INR 2,14,760 still pendingMinor compliance overhang
26 Jun 2026Trading window closed ahead of Q1 FY27 resultsRoutine
18 Jul 2026FY26 Annual Report (66th) releasedDisclosure
7 Aug 2026Q1 FY27: revenue INR 193.8 Cr (+3.9% YoY, -4.1% QoQ), EBITDA INR 19.4 Cr (+41.6%), PAT INR 11.4 Cr (+37.6%); promoter-group reclassification requests withdrawn; revised RPT policy adoptedMargin recovery confirmed
12 Aug 202666th AGM held; FY26 final dividend of INR 1.50 approved (record date 5 Aug 2026)Payout
19 Aug 2026Q1 FY27 investor presentation: ROCE 19.18%, production 491 MT (+19.5%), top-5 customer share down to 20%; 15–20% growth guidance reiterated; bisoprolol added to pipelineGuidance reaffirmed
Aug–Sep 2026Share price rallies to about INR 93–99 (52-week high about INR 99.5) after Q1 resultsMarket response
16 Oct 2026Stock closes at INR 83.05 (market cap about INR 832 Cr); next results expected around 13 Nov 2026 (S&P estimate)Valuation reset

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

8 charts
Income Statement: Revenue & Gross Profit: Total revenue incl. other income (company) rose from INR 4,918 Mn in FY2022 to INR 7,760 Mn in FY2026.
Anuh Pharma Limited — Income Statement: Revenue & Gross Profit
Series (INR Mn)FY2022FY2023FY2024FY2025FY2026
Total revenue incl. other income (company)4,9185,3706,5906,7107,760
Revenue from operations4,8665,2756,4706,6157,717
Gross profit (S&P)1,0571,2001,5561,5481,631

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.